Researchers in this abstract parallel session will share the results of recent clinical trials in MASH.

As the landscape of liver disease evolves, so too must our tools for evaluating therapeutic efficacy and disease progression.  This cutting-edge session will explore the latest advances and ongoing debates surrounding clinical trial and real-world endpoints for metabolic dysfunction-associated alcohol-related liver disease (MetALD), alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), and alpha-1 antitrypsin deficiency (AATD). For MetALD, we will present the consensus endpoints developed by the AASLD/EASL MetALD Working Groups.  Experts will address the challenges of defining meaningful and harmonized endpoints across overlapping phenotypes, the role of biomarkers and imaging, and regulatory considerations in early- and late-phase trials. Emphasis will be placed on how to tailor endpoints to the unique pathophysiology of each disease while also considering patient-centered outcomes and emerging surrogate markers. This session is essential for clinicians, researchers, and industry stakeholders involved in trial design and drug development for liver diseases. 

This session will review the key events leading to the discovery of the Hepatitis B Virus (HBV), the global public health impact HBV has had on human health, the development of an effective vaccine to prevent transmission that has reduced incident infection in endemic regions, and the state of current elimination efforts. Faculty members will also cover the history of the development of therapy for HBV and the effectiveness of current therapy to prevent complications of chronic HBV infection. Finally, new therapies in development for a cure for chronic HBV infection will be reviewed.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

This session will explore how clinical and molecular markers can inform prognosis and therapeutic strategy in chronic hepatitis B. Presentations will compare the impact of current antiviral therapies on hepatocellular carcinoma (HCC) risk and examine how partial virologic responses and HBsAg decline correlate with long-term outcomes. The session will also address the evolving role of therapy discontinuation in HBeAg-negative patients, the utility of quantitative HBsAg and HBV RNA in distinguishing inactive carriers from those with partial cure, and the predictive value of biomarkers in selecting candidates for functional cure.

Presenters in this session will share their research into novel techniques to understand hepatobiliary neoplasia, including the interaction of known carcinnogenic stimuli and the immune system.

This abstract session will present the latest research on complications of portal hypertension, including hepatic encephalopathy, ascites, and HRS-AKI. Authors will present novel findings and innovative approaches in diagnosing and managing these conditions, which are pivotal challenges in patients with advanced liver disease.